OMT-28

DRUG3 trials

Sponsors

Omeicos Therapeutics GmbH

Conditions

Atrial FibrillationHealthy VolunteersPrimary Mitochondrial Disease

Phase 1

Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects

CompletedNCT03078738

Omeicos Therapeutics GmbHHealthy Volunteers

Start: 2017-02-08End: 2018-03-12Updated: 2018-09-28

Phase 2

Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)

CompletedNCT03906799

Omeicos Therapeutics GmbHAtrial Fibrillation

Start: 2019-03-19End: 2020-03-20Updated: 2021-09-09

OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)

CompletedNCT05972954

Omeicos Therapeutics GmbHPrimary Mitochondrial Disease

Start: 2023-05-22End: 2025-07-30Updated: 2026-01-22

Related Papers

Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study.

2020-07-106 citations